Drug Combination Details
| General Information of the Combination (ID: C78557) | |||||
|---|---|---|---|---|---|
| Name | Bufalin NP Info | + | MK2206 Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Multiple myeloma
[ICD-11: 2A83]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | AKT1 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | NCI-H929 | CVCL_1600 | Plasma cell myeloma | Homo sapiens | ||
| U266B1 | CVCL_0566 | Plasma cell myeloma | Homo sapiens | |||
| LP-1 | CVCL_0012 | Plasma cell myeloma | Homo sapiens | |||
| RPMI-8226 | CVCL_0014 | Plasma cell myeloma | Homo sapiens | |||
| Experimental
Result(s) |
MK2206 enhances the cytocidal effects of bufalin in multiple myeloma by inhibiting the AKT/mTOR pathway. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | MK2206 enhances the cytocidal effects of bufalin in multiple myeloma by inhibiting the AKT/mTOR pathway. Cell Death Dis. 2017 May 11;8(5):e2776. | |||
